Clinical Impact of Liraglutide as a Treatment of Obesity
Heshma Alruwaili,1 Babak Dehestani,1 Carel W le Roux1,2 1Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland; 2Diabetes Research Group, School of Biomedical Sciences, Ulster University, Belfast, UKCorrespondence: Heshma Alruwaili Email alruwaily85@hot...
Guardado en:
| Autores principales: | Alruwaili H, Dehestani B, le Roux CW |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a6dd020fdd0549d2a9e2f4e412d332e9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
por: Albaker W, et al.
Publicado: (2021) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010) -
First GLP-1 analog liraglutide: the result of clinical trails on efficacy
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011) -
Weight loss medications in Canada – a new frontier or a repeat of past mistakes?
por: Wharton S, et al.
Publicado: (2017) -
Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity
por: Vladimir Ivanovich Kudinov, et al.
Publicado: (2011)